Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of gene therapy in treating
patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to
therapy or came back after an original response receiving stem cell transplant. In gene
therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are
introduced into the stem cells in the laboratory to make the gene therapy product used in
this study. The type of anti-HIV genes and therapy in this study may make the patient's
immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with
HIV-1.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
California Institute for Regenerative Medicine (CIRM) National Cancer Institute (NCI)